CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes therapy(City of Hope Medical Center)

N/A

Report date: 2024/06/11 20:00:08

Base Information

Drug NameCD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes therapy(City of Hope Medical Center)
Drug Alias NameCD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T Cells therapy(City of Hope Medical Center)CD19R(EQ)28zeta/EGFRt+ Naive and Memory T Cells therapy(City of Hope Medical Center)CD19R(EQ)28zetaEGFRt+ Tn/mem Cells therapy(City of Hope Medical Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic NeoplasmsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A